Agios Pharmaceuticals (AGIO) vs Sarepta Therapeutics (SRPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Agios Pharmaceuticals (AGIO) has outperformed Sarepta Therapeutics (SRPT) over the past year, losing 22.2% versus a loss of 24.3%. Over five years, AGIO leads with a -31.3% price change compared with -79.2% for SRPT. Agios Pharmaceuticals is the larger company by market cap ($1.90 billion vs $1.85 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGIO | SRPT |
|---|---|---|
| Share price | $31.79 | $17.50 |
| Market cap | $1.90B | $1.85B |
| 1-day change | +0.22% | +1.10% |
| YTD return | +16.79% | -18.68% |
| 1-year return | -22.22% | -24.31% |
| 5-year return | -31.31% | -79.21% |
| Forward P/E | — | 7.26 |
| EPS (TTM) | $-7.03 | $-1.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $46.00 | $24.68 |
| 52-week low | $22.24 | $14.68 |
| Distance from 52-week high | -30.89% | -29.09% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +44.70% | +24.17% |
| Average volume | 1.05M | 2.98M |
| Shares outstanding | 59.70M | 105.63M |
| Employees | 539 | 835 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Agios Pharmaceuticals
AGIO stock →Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
Health Care · Biotechnology: Pharmaceutical Preparations · 539 employees
About Sarepta Therapeutics
SRPT stock →Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene.
Health Care · Biotechnology: Pharmaceutical Preparations · 835 employees
AGIO vs SRPT FAQ
Which is bigger, Agios Pharmaceuticals or Sarepta Therapeutics?
Agios Pharmaceuticals (AGIO) is larger, with a market capitalization of $1.90B compared with $1.85B for Sarepta Therapeutics (SRPT).
Which stock has performed better over the past year, AGIO or SRPT?
AGIO returned -22.22% over the past 12 months, compared with -24.31% for SRPT (price return, excluding dividends). Past performance does not predict future results.
Are Agios Pharmaceuticals and Sarepta Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.